NRL Capital

NRL Capital is a China-based private equity firm specializing in venture capital and secondary investments. The firm focuses on early-stage and growth-stage investments across various sectors, including biotechnology, healthcare, medical, pharmaceutical, semiconductor, electronic design automation (EDA), biopharma, innovation management, and textiles. NRL Capital operates in China, the United States, and Singapore, with offices in Beijing, Shanghai, Suzhou, Shenzhen, and Singapore.

The firm's investment strategy encompasses direct investments, secondary investments, and fund-of-funds. NRL Capital leverages its global networks to support portfolio companies' globalization and connects global companies with its ecosystem in China. The firm also provides liquidity solutions to both limited partners and general partners through secondary investments. Additionally, NRL Capital manages funds of funds, focusing on diversified portfolios to optimize returns.

NRL Capital's management team comprises experienced professionals with over 20 years in private equity investment and fund management. The team includes Founding Partners Xianghong Lin and Shuang Deng, who have held leadership positions in various investment institutions. The firm's commitment to sustainability is evident in its ESG practices, investing in companies that drive global sustainability through technological innovation. Notable investments include NTX, which empowers the textile industry to reduce carbon emissions, and Garea, which enhances healthcare accessibility in China.